Table 1.
Variable (unit) | All subjects (n = 746) | Patients without ID (N = 412) | Patients with ID (N = 334) | P‐value ID vs. no ID |
---|---|---|---|---|
Age (years) | 68 ± 13 | 68 ± 12 | 69 ± 13 | 0.8 |
Male/n (%) | 395 (53%) | 251 (61) | 144 (43) | <0.0001 |
Weight (kg) | 77.1 ± 16 | 78.5 ± 16.0 | 75.2 ± 15.6 | 0.01 |
Body mass index (kg/m2) | 27.5 ± 6 | 27.6 ± 5.0 | 27.4 ± 6.9 | 0.6 |
Systolic blood pressure (mmHg) | 136 ± 22 | 136.2 ± 21.5 | 135.0 ± 21.7 | 0.5 |
Diastolic blood pressure (mmHg) | 80 ± 14 | 80.4 ± 13.7 | 78.5 ± 14.1 | 0.09 |
Stroke subtype (%) | 0.014 | |||
Ischaemic | 648 (87%) | 370 (90%) | 278 (83%) | |
Haemorrhagic | 98 (13%) | 43 (10%) | 55 (16%) | |
TOAST criteria for ischaemic stroke aetiology a (%) | 0.6 | |||
Cardioembolic | 216 (29) | 115 (28) | 101 (30) | |
Macroangiopathic | 223 (30) | 125 (30) | 98 (29) | |
Microangiopathic | 143 (19) | 91 (22) | 52 (16) | |
Unknown | 157 (21) | 78 (19) | 79 (24) | |
Rare causes | 5 (<1) | 3 (<1) | 2 (<1) | |
Treated on stroke unit, n (%) | 393 (53) | 195 (47) | 198 (59) | 0.003 |
Thrombolytic therapy, n (%) | 92 (12) | 45 (11) | 47 (14) | 0.3 |
Co‐morbidities (%) | ||||
Anaemia | 343 (46) | 140 (34) | 203 (61) | <0.0001 |
Arterial hypertension | 502 (67) | 282 (68) | 220 (66) | 0.8 |
Ischaemic heart disease | 106 (14) | 57 (14) | 49 (15) | 0.8 |
Atrial fibrillation | 159 (21) | 77 (19) | 82 (25) | 0.3 |
Diabetes mellitus | 186 (25) | 99 (24) | 87 (26) | 0.1 |
Adipositas | 84 (11) | 52 (13) | 32 (10) | 0.3 |
Dyslipidaemia | 218 (29) | 126 (31) | 92 (28) | 0.6 |
Stroke severity at baseline, median [IQR] | ||||
Reha‐Barthel index | 30 [85] | 40 [80] | 20 [86] | <0.001 |
Motricity index | 74 [55] | 77 [41] | 64 [66] | <0.0001 |
Trunk control test | 87 [52] | 100 [39] | 61 [76] | <0.0001 |
Functional ambulatory category | 3.0 [5.0] | 4.0 [4.0] | 1.0 [4.0] | <0.0001 |
Creatinine (μmol/L) | 87 ± 62 | 89 ± 67 | 85 ± 56 | 0.3 |
Glomerular filtration rate, MDRD (mL/min/1.73 m2) | 88 ± 39 | 85 ± 34 | 90 ± 45 | 0.09 |
C‐reactive protein, CrP (mg/L) | 17 ± 32 | 10.8 ± 22.1 | 25.0 ± 41.5 | <0.0001 |
Uric acid (μmol/L) | 338 ± 123 | 349 ± 120 | 324 ± 126 | 0.01 |
Leucocytes (/nL) | 8.3 ± 3.2 | 7.84 ± 3.01 | 8.92 ± 3.31 | <0.0001 |
Glutamate oxaloacetate transaminase, GOT (U/L) | 0.53 ± 0.27 | 0.56 ± 0.27 | 0.51 ± 0.28 | 0.02 |
Glutamate pyruvate transaminase, GPT (U/L) | 0.66 ± 0.57 | 0.70 ± 0.58 | 0.61 ± 0.55 | 0.10 |
Haemoglobin (g/dL) | 12.6 ± 1.6 | 13.2 ± 1.6 | 12.1 ± 1.6 | <0.0001 |
Haematocrit | 0.37 ± 0.05 | 0.39 ± 0.05 | 0.36 ± 0.05 | <0.0001 |
Mean corpuscular haemoglobin, MCH (fmol) | 1.89 ± 0.2 | 1.94 ± 0.24 | 1.84 ± 0.13 | <0.0001 |
Mean corpuscular haemoglobin concentration, MCHC (mmol/L) | 21.1 ± 0.49 | 21.2 ± 0.44 | 20.9 ± 0.51 | <0.0001 |
Mean corpuscular volume, MCV (fL) | 89.5 ± 4.8 | 90.7 ± 4.31 | 87.8 ± 4.96 | <0.0001 |
Retikulocyte count (‰) | 15.8 ± 8.5 | 14.61 ± 7.82 | 17.39 ± 8.96 | <0.0001 |
Reticulocyte production index, RPI (%) | 0.95 ± .04 | 0.95 ± 0.38 | 0.94 ± 0.43 | <0.0001 |
Ferritin (μg/L) | 322 ± 294 | 388 ± 297 | 240 ± 271 | |
Transferrin saturation, TSAT (%) | 25.0 ± 11.7 | 31.6 ± 10.2 | 16.9 ± 7.5 | |
Soluble transferrin receptor, sol TfR (mg/L) | 3.1 ± 1.3 | 2.72 ± 0.91 | 3.64 ± 1.55 | <0.0001 |
TOAST, the Trial of ORG 10172 in Acute Stroke Treatment—classifies ischaemic stroke aetiology.